Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CEO Patrick Smith sold 10,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the transaction, the chief executive officer directly owned 3,090,997 shares in the company, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Axon Enterprise Price Performance
AXON stock opened at $550.19 on Friday. The company has a market cap of $43.42 billion, a PE ratio of 361.97, a price-to-earnings-growth ratio of 15.67 and a beta of 1.48. The company has a current ratio of 2.53, a quick ratio of 2.89 and a debt-to-equity ratio of 0.53. The stock has a 50-day moving average price of $538.95 and a two-hundred day moving average price of $627.46. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business had revenue of $796.72 million during the quarter, compared to analysts' expectations of $755.29 million. During the same quarter in the previous year, the business earned $2.08 EPS. The company's revenue for the quarter was up 38.5% on a year-over-year basis. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Westside Investment Management Inc. raised its position in shares of Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company's stock worth $225,000 after acquiring an additional 13 shares during the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company's stock worth $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital lifted its holdings in shares of Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company's stock valued at $284,000 after purchasing an additional 14 shares in the last quarter. Evergreen Capital Management LLC grew its holdings in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after buying an additional 15 shares in the last quarter. Finally, STF Management LP lifted its stake in Axon Enterprise by 1.4% during the 2nd quarter. STF Management LP now owns 1,164 shares of the biotechnology company's stock valued at $964,000 after acquiring an additional 16 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an "outperform" rating on the stock in a research note on Wednesday. Citigroup reaffirmed a "buy" rating on shares of Axon Enterprise in a report on Wednesday. Weiss Ratings restated a "hold (c-)" rating on shares of Axon Enterprise in a report on Monday, December 29th. The Goldman Sachs Group decreased their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. Finally, Robert W. Baird set a $800.00 price objective on Axon Enterprise in a research report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and an average target price of $762.93.
Get Our Latest Report on AXON
Axon Enterprise News Roundup
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Q4 beat and robust guidance — Axon reported a double beat (EPS and revenue), ~39% revenue growth, a large increase in future contracted bookings and raised multi‑year sales targets; investors are calling out AI adoption across devices + software as a growth accelerator. Axon's Q4 Earnings Top Estimates
- Positive Sentiment: AI narrative fuels demand — multiple outlets highlight that Axon’s integration of AI into body cameras, evidence management and report drafting is boosting subscription take‑up and upsells, supporting the stock rebound. Taser-maker Axon pops 18% as AI boosts demand
- Neutral Sentiment: Analysts updating models — several firms trimmed price targets after the print (Piper Sandler, Barclays, Morgan Stanley, UBS) while many maintain positive/overweight ratings; these are adjustments reflecting the stock’s recent volatility rather than a rejection of the beat. These Analysts Cut Their Forecasts On Axon After Q4 Results
- Neutral Sentiment: Short‑interest data reported as anomalous in recent filings (zero/NaN figures); nothing actionable from that data point for now.
- Negative Sentiment: Some firms voice caution — recent analyst pieces from Morgan Stanley and UBS flagged downside scenarios and issued more pessimistic near‑term outlooks, which could cap upside if execution or margins slip. Morgan Stanley Issues Pessimistic Forecast for Axon Enterprise
- Negative Sentiment: Profitability concerns remain — commentators note that revenue and bookings growth outpaced profit improvement; investors should watch margin recovery and free‑cash‑flow conversion. Axon Stock Is On Fire, But Here's the Bad News
- Negative Sentiment: Insider sale disclosed — CEO sold 10,000 shares (~$5.0M) on Feb. 25; small relative to holdings but worth noting for traders monitoring insider activity. SEC Form 4 — Insider Sale
About Axon Enterprise
(
Get Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
